Santarus Reports Fourth Quarter and Full Year 2010 Financial Results

Santarus, Inc. SNTS, a specialty biopharmaceutical company, today reported financial and operating results for the quarter and full year ended December 31, 2010. Key financial results for the 2010 fourth quarter: Total revenues of $25.9 million. Net loss of $2.1 million, or $0.03 per share, which included approximately $5.4 million in success-based milestones expensed in the quarter. Key financial results for the 2010 full year: Total revenues of $125.4 million. Net loss of $18.5 million, or $0.31 per share, which included approximately $7.1 million in one-time restructuring charges, a $15.0 million upfront fee paid for North American rights to RHUCIN® (recombinant human C1 inhibitor) and approximately $5.4 million in success-based milestones. Cash, cash equivalents and short-term investments of $60.8 million as of December 31, 2010.